OncoMatch/Clinical Trials/NCT06459687
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Is NCT06459687 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab for cervical cancer.
Treatment: Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab — The goal of this clinical trial is to evaluate the efficacy and safety of Socazolimab combined with chemotherapy with or without bevacizumab as first-Line treatment in persistent, recurrent, or metastatic cervical cancer. The main question it aims to answer is: Does Socazolimab combined with chemotherapy with or without bevacizumab better benefit patients with persistent, recurrent, or metastatic cervical cancer as first-line treatment compared with placebo combined with chemotherapy with or without bevacizumab. Participants will be treated with Socazolimab/placebo + chemotherapy ± bevacizumab) for 6\~8 cycles (Q3w), following maintenance treatment of Socazolimab/placebo (Q3w).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-angiogenic therapy (bevacizumab)
Prior anti-angiogenic therapy (e.g., bevacizumab)
Cannot have received: immune checkpoint inhibitor (anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody)
immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.)
Cannot have received: immune costimulator targeting therapy (antibodies against ICOS, CD40, CD137, GITR, OX40)
targeting immune costimulators (e.g. antibodies against ICOS, CD40, CD137, GITR, OX40 targets, etc.) and any treatment targeting the immune mechanism of tumor
Cannot have received: anti-tumor therapy
Anti-tumor therapy within 4 weeks before randomization
Lab requirements
Blood counts
good organ function required; see laboratory examination results during screening
Kidney function
good organ function required; see laboratory examination results during screening
Liver function
good organ function required; see laboratory examination results during screening
Laboratory examination results during the screening period indicate that the subject has good organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06459687 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-angiogenic therapy, immune checkpoint inhibitor, immune costimulator targeting therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages